Endocrine Abstracts

Background: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system. However, there is no in vitro data on TMZ sensitivity and the expression of MGMT and MMR components in PNETs. Moreover, the effect of TMZ exposure on chemosensitivity and exp...

Background: A metastatic mesenteric mass is a hallmark of small intestinal neuroendocrine tumours (SI-NETs). However, little is known about the evolution of a SI-NET-associated mesenteric mass over time.Methods: Retrospectively, 530 patients with proven SI-NET and ≥2 available CT-scans were assessed for clinical characteristics at diagnosis and the presence and growth of a mesenteric mass on every consecutive CT-scan until end of follow-up or resec...